These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 28823521)

  • 1. The potential and promise of IL-15 in immuno-oncogenic therapies.
    Robinson TO; Schluns KS
    Immunol Lett; 2017 Oct; 190():159-168. PubMed ID: 28823521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
    Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
    Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
    Stoklasek TA; Schluns KS; Lefrançois L
    J Immunol; 2006 Nov; 177(9):6072-80. PubMed ID: 17056533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation.
    Van den Bergh JM; Lion E; Van Tendeloo VF; Smits EL
    Pharmacol Ther; 2017 Feb; 170():73-79. PubMed ID: 27777088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
    Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 15 as a promising candidate for tumor immunotherapy.
    Jakobisiak M; Golab J; Lasek W
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
    Zhang S; Zhao J; Bai X; Handley M; Shan F
    Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-15: new kid on the block for antitumor combination therapy.
    Van den Bergh JM; Van Tendeloo VF; Smits EL
    Cytokine Growth Factor Rev; 2015 Feb; 26(1):15-24. PubMed ID: 25306466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
    Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
    Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing Natural Killer and CD8
    Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-15: targeting CD8+ T cells for immunotherapy.
    Diab A; Cohen AD; Alpdogan O; Perales MA
    Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-15 biology and its therapeutic implications in cancer.
    Steel JC; Waldmann TA; Morris JC
    Trends Pharmacol Sci; 2012 Jan; 33(1):35-41. PubMed ID: 22032984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
    Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
    Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-15 in the Combination Immunotherapy of Cancer.
    Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
    Front Immunol; 2020; 11():868. PubMed ID: 32508818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
    Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
    J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
    Ochoa MC; Fioravanti J; Rodriguez I; Hervas-Stubbs S; Azpilikueta A; Mazzolini G; Gúrpide A; Prieto J; Pardo J; Berraondo P; Melero I
    Cancer Res; 2013 Jan; 73(1):139-49. PubMed ID: 23149919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis.
    Burkett PR; Koka R; Chien M; Chai S; Boone DL; Ma A
    J Exp Med; 2004 Oct; 200(7):825-34. PubMed ID: 15452177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.